Investor Relations

Stock Quote - Ticker Tape

 

SEC Filings

  o View CEL-SCI's SEC Filings  
       

CEL-SCI Presentations

  February 9, 2016
NEW PRESENTATION Geert Kersten at the 18th Annual BIO CEO & Investor Conference

 
  January 2016
NEW INTERVIEW Interview with Dr. Eyal Talor, Chief Scientific Officer

 
  January 2016
NEW PRESENTATION Geert Kersten at the Noble Financial Capital Markets' 12th Annual Investor Conference

 
  December 2015
Geert Kersten at the LD Micro Main Event

 
  October 2015
Interview with Geert Kersten at the Dawson James Small Cap Growth Conference 2015

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  FEBRUARY 9, 2016
NEW STORY CEL-SCI Corporation Reports First Quarter Fiscal 2016 Financial Results
  FEBRUARY 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in January for Its Phase 3 Head and Neck Cancer Trial
  JANUARY 8, 2016
NEW STORY CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum For 2016
  JANUARY 5, 2016
NEW STORY CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial
  DECEMBER 11, 2015
NEW STORY CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments
  DECEMBER 1, 2015
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in November for Its Phase 3 Head and Neck Cancer Trial
  NOVEMBER 17, 2015
NEW STORY CEL-SCI Is Granted a New European Patent on Its Phase 3 Investigational Cancer Immunotherapy Multikine
  NOVEMBER 4, 2015
NEW STORY CEL-SCI's Rheumatoid Arthritis Vaccine Selected for Commercialization & Program Niche Analysis Plan by U.S. National Institutes of Health
  NOVEMBER 2, 2015
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in October for Its Phase 3 Head and Neck Cancer Trial
  OCTOBER 28, 2015
NEW STORY CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $11.5 Million
  OCTOBER 14, 2015
CEL-SCI to Receive Up to $5,000,000 in Litigation Funding to Support Its Arbitration Suit Against Former CRO
  OCTOBER 5, 2015
Ergomed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI's Phase 3 Head and Neck Cancer Trial

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com